$5.2 billion deal underscores Exscientia's AI bona fides

Building on a long and growing list of collaborations, artificial intelligence (AI) firm Exscientia (Nasdaq: EXAI) has agreed terms for a new deal with French pharma major Sanofi (Euronext: SAN).

The research collaboration and license agreement, which could be worth billions to the Oxford-based company, covers the development of up to 15 novel small molecule candidates across oncology and immunology.

Exscientia brings to the table its end-to-end AI-driven platform, which uses actual patient samples.